ALTEOGEN Inc Total Liabilities

Latest as of June 2026: ₩192.66 Billion KRW ≈ $130.57 Million USD

ALTEOGEN Inc total liabilities. Based on the latest financial reports, ALTEOGEN Inc (196170) has total liabilities worth ₩192.66 Billion KRW (≈ $130.57 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of ALTEOGEN Inc to measure how many days the company can operate on defensive assets alone.

Total Liabilities of ALTEOGEN Inc (2014–2025)

Total liabilities of ALTEOGEN Inc from 2014 to 2025. This chart illustrates how ALTEOGEN Inc's total liabilities have evolved over time, based on quarterly financial data. Check 196170 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

ALTEOGEN Inc Competitors by Total Liabilities

The table below lists competitors of ALTEOGEN Inc ranked by their total liabilities.

Company Country Total Liabilities
Repligen Corporation
NASDAQ:RGEN
USA $838.15 Million
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
China CN¥16.19 Billion
Advanced Drainage Systems Inc
NYSE:WMS
USA $2.55 Billion
YARA INTL ASA ADR NK170
F:IU20
Germany €8.69 Billion
Walgreens Boots Alliance Inc
NASDAQ:WBA
USA $62.09 Billion
Industrial Bank Of Korea
KO:024110
Korea ₩463.84 Trillion
Stifel Financial Corporation
NYSE:SF
USA $38.89 Billion
Dino Polska SA
WAR:DNP
Poland zł6.34 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down ALTEOGEN Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of ALTEOGEN Inc.

Liquidity & Leverage Metrics

ALTEOGEN Inc Total Liabilities Ratios Explained

ALTEOGEN Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.76 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.26 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ALTEOGEN Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ALTEOGEN Inc (2014–2025)

The table below shows the annual total liabilities of ALTEOGEN Inc from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩244.30 Billion
≈ $165.56 Million
+81.07%
2024-12-31 ₩134.92 Billion
≈ $91.43 Million
+24.63%
2023-12-31 ₩108.26 Billion
≈ $73.37 Million
+11.92%
2022-12-31 ₩96.73 Billion
≈ $65.55 Million
-21.74%
2021-12-31 ₩123.61 Billion
≈ $83.77 Million
+340.77%
2020-12-31 ₩28.04 Billion
≈ $19.00 Million
+75.31%
2019-12-31 ₩16.00 Billion
≈ $10.84 Million
+236.41%
2018-12-31 ₩4.76 Billion
≈ $3.22 Million
+50.08%
2017-12-31 ₩3.17 Billion
≈ $2.15 Million
+16.44%
2016-12-31 ₩2.72 Billion
≈ $1.84 Million
+226.01%
2015-12-31 ₩834.62 Million
≈ $565.61K
-60.88%
2014-12-31 ₩2.13 Billion
≈ $1.45 Million
--

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$10.37 Billion
₩15.30 Trillion KRW
Market Cap Rank
#2113 Global
#42 in Korea
Share Price
₩220000.00
Change (1 day)
-1.35%
52-Week Range
₩213500.00 - ₩559000.00
All Time High
₩559000.00
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more